



European Federation of Pharmaceutical
Industries and Associations

EFPIA Annual Report 2017

Unlocking tomorrow's cures






Table of contents

Introduction	3
Foreword	4
About EFPIA	5
EFPIA Activity 2017	6
Continuing to drive innovation	7
The impact of medicines	8
Collaboration	9
The economic impact of the industry	10
The impact of vaccines	11
EFPIA Governance	12



Introduction

We won't rest



NATHALIE MOLL
Director General
EFPIA

“


Since no single sector has the solutions to many challenges that we face, we have been particularly keen to develop strategic partnerships in order to tackle some of these issues.

”



Looking ahead,

the science is very exciting. Introducing these new technologies into healthcare system is challenging.



We look forward to working with partners in the healthcare and research space in order to face these challenges.



We want to contribute to a healthier future for Europe - a future based on prevention, innovation, access and better outcomes for patients.



The range and speed of innovation truly makes this an exciting time to be EFPIA President.

Foreword by the President

Our scientists delivered inspiring results in bringing new treatments to patients last year: The EMA approved 92 new medicines in 2017, and of those 35 had a new active substance.



STEFAN OSCHMANN
EFPIA President
Chairman of the Executive Board
and CEO of Merck

Yet the story of our industry, and the passion that motivates all of us who work in it, is not about numbers. It is about the myriad of ways in which we are able to deliver healthcare and transform the lives of patients. We are just beginning to open the door onto the world made possible by genomics, data analytics and combination therapies. The coming years will not only continue to bring new treatments, they will also be ones where we can expect to realize the potential of healthcare data in shaping health systems and patient care.

Rapid change can be daunting, and these new opportunities also mean challenges that will test the limits of structures and processes that have developed over decades. EFPIA's members are committed to working with all stakeholders to make sure that our regulatory framework can adapt to the rapidly changing science.

Working together, we can take on the ambition of strengthening Europe's position as the leading centre for clinical research. One idea that can help achieve this is the Integrative Patient Screening Initiative (IPSI). Bringing together pharmaceutical companies, investigators, regulators and patients, IPSI would establish a common platform for sharing of patient screening data and biomarker results. This would allow patients considering participating in a clinical study to know that their screening results will be evaluated across multiple studies, increasing their chances of finding one that matches their personal medical profile.

Maintaining Europe's leadership within the global innovation ecosystem will be no easy feat. We are competing with other research centres around the world in terms of skills, infrastructure and IP environment. Keeping up with the global competition requires preserving the existing delicate balance between incentives, without which there are no new medicines, and the need to ensure the sustainability of our healthcare systems.

Tackling these challenges requires us to work in close partnership with stakeholders from all sectors. EFPIA stands ready to partner with all those who share our vision: bringing innovative treatments to patients right across Europe – and beyond.

Stefan Oschmann



About EFPIA

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

OUR VISION

EFPIA's vision is for a healthier future for Europe. A future based on prevention, innovation, access to new treatments and better outcomes for patients.

OUR MISSION

EFPIA's mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.

OUR VALUES

Professionalism
Openness
Integrity
Respect

EFPIA specialised groups

European Biopharmaceutical Enterprises (EBE) represents the voice of biopharmaceutical companies of all sizes in Europe. Established in 2000, EBE is recognised as the leading biopharmaceutical association in Europe.

Vaccines Europe (VE) represents major innovative research-based global vaccine companies as well as small and medium-sized enterprises operating in Europe



2
specialised
groups

EFPIA Activity 2017

LEGAL AFFAIRS

Second disclosure of transfers of value to HCPs and HCOs around Europe by EFPIA members as part of the industry commitment to transparency

ECONOMIC AND SOCIAL AFFAIRS

In a meeting facilitated by the EUnetHTA Directorate and supported by DG SANTE, Heads of HTA agencies and Heads of Europe of several EFPIA member companies discussed what both sides can contribute to avoid duplication as well as which challenges would need to be addressed to facilitate increased submission of dossiers for joint work within EUnetHTA JA3.

STRATEGY AND HEALTHCARE SYSTEMS

Launch of RAND report on Value of Health data during a seminar in Brussels with speakers from EFPIA, the Commission, academia and patient organisations.

INTERNATIONAL AFFAIRS

EFPIA and AIFD held a strategy workshop in Brussels in order to discuss strategy and advocacy on forced localisation and Customs Union, with the participation of the EU Commission and the Turkish Mission to the EU.

SCIENCE POLICY AND REGULATORY AFFAIRS

- 2017 Brochure putting animal welfare principles and 3Rs into action
- CFDA, China was approved as new member of ICH

COMMUNICATIONS AND PARTNERSHIPS

EFPIA launch the #WeWontRest campaign

VACCINES EUROPE

Introduction of the 1st Early Career Research Prize in Vaccinology R&D by IUIS and Vaccines Europe to promote and foster a younger generation of scientists.

SCIENCE POLICY AND REGULATORY AFFAIRS

- Launch of the Digital Health Society Declaration under Estonian Presidency
- Publication of EPAA paper 'Towards global harmonization of 3Rs in biologicals' on a project co-led by EFPIA which led to the deletion of an animal test from 49 monographs.

LEGAL AFFAIRS

- Publication of the document 'Working together with patient groups'

VACCINES EUROPE

- Vaccines Europe developed the Position paper on 'Potential labeling/packaging improvements to facilitate vaccine supply'
- Vaccines Europe developed the Position Paper on 'Improvement of Healthy Authority Systematic Independent Release through a risk based approach'

INTERNATIONAL AFFAIRS

- EFPIA welcomed the entry into force of the EU-Canada CETA agreement, in which several key IP issues of the industry were included.
- EFPIA and Eurocham Vietnam Board members organised a joint outreach programme in Brussels to highlight industry concerns with implementation of the Vietnam FTA.

SCIENCE POLICY AND REGULATORY AFFAIRS

- Life Sciences Roundtable meeting on REACH was held by EFPIA in collaboration with other life sciences industries while the Commission, European Chemicals Agency (ECHA) and European Medicines Agency (EMA) participated in the fruitful discussion leading into more open and frequent interaction between the industry on the impact of REACH on our sector.

STRATEGY AND HEALTHCARE SYSTEMS

EFPIA DG Nathalie Moll participated in the EFPIA-supported Value of Health roundtable, discussing the role of outcomes measures for integrated care and reducing waste in healthcare.

VACCINES EUROPE

Vaccines Europe commented the EC/EMA Preliminary position paper on ICH on vaccines. Vaccines Europe presented the ICH strategy paper during the ICH Management Committee meeting and committed to working further on the ICH vaccines priorities details proposals together with others associations.

SCIENCE POLICY AND REGULATORY AFFAIRS

- ERT joins as Partner in Research
- Partners in Research cross-sectorial workshop on digital health: research and policy
- The ICH Assembly met in Geneva
- Positive evaluation of the IMI PARADIGM proposal. EFPIA co-leads the project

INTERNATIONAL AFFAIRS

EFPIA and AIPM, in cooperation with the Eurasian Commission, organised a workshop in Moscow on "Common market of medicines within the Eurasian Economic Union". The purpose was further developing regulatory convergence between the Eurasian Commission and the EU.

EFPIA Vice-President Jean-Christophe Tellier represented EFPIA during the annual EFPIA Japan Days, co-organised with EFPIA Japan.

SCIENCE POLICY AND REGULATORY AFFAIRS

- EFPIA publishes the Eco-Pharmaco-Stewardship brochure in collaboration with AESGP and Medicines for Europe.
- HSA, Singapore was approved as new member of ICH

ECONOMIC AND SOCIAL AFFAIRS

EFPIA and EUnetHTA members met in a technical meeting to discuss progress within the Joint Action 3, focusing on company experiences of joint assessments and their use at national level and recommendations on how to improve established processes.

COMMUNICATIONS AND PARTNERSHIPS

Publication of the EFPIA Health Collaboration Guide, showcasing best practice examples of collaborative projects between industry and patient organisations

SCIENCE POLICY AND REGULATORY AFFAIRS

Multi-stakeholder paediatric oncology strategy workshop (ACCELERATE platform).

STRATEGY AND HEALTHCARE SYSTEMS

EFPIA organised a roundtable on outcomes measures in Health Systems Performance Assessment with the Commission, the OECD and patient organisations.

SCIENCE POLICY AND REGULATORY AFFAIRS

- Heads of R&D kick off the IMI Think Big process (Immunology, AMR, Big Data, Clinical Trials)
- EU and US agreed on a mutual recognition on GMP inspections.
- Kick-off meeting of the new task force on big data established by the Heads of Medicines Agencies (HMA) and EMA.

FEB 17

APR 17

MAY 17

JUN 17

JUL 17

AUG 17

SEP 17

OCT 17

NOV 17

DEC 17

JAN 18

INTERNATIONAL AFFAIRS

EFPIA responded to the EC public consultation on EU-Mexico trade relations. The key industry priorities in this context were further outlined in a detailed position paper submitted to the EC.

SCIENCE POLICY AND REGULATORY AFFAIRS

- Stakeholders workshop on culture of care to enhance lab animal welfare beyond EU legal requirements.
- Clarivate & Nokia join as Partner in Research.
- EFPIA's response on revision of First in Human Guideline (FIH) was submitted.

EFPIA

New Director General, Nathalie Moll joins EFPIA.

INTERNATIONAL AFFAIRS

EFPIA participated in high-level discussions at the OECD Trade Committee meeting in Paris, also holding exchanges with various Embassies on the sidelines.

SCIENCE POLICY AND REGULATORY AFFAIRS

- MedTronic joins as Partner in Research
- EFPIA and Preclinical Assessors Meeting was organized on preclinical development. EFPIA experts interacted and shared their knowledge with the regulators from all national competent authorities.

VACCINES EUROPE

Vaccines Europe published a paper on priorities for vaccination policies in Europe to contribute to the debate around the Commission initiatives on vaccination.

INTERNATIONAL AFFAIRS

- EFPIA held a Joint Industry Strategy Session together with global sister associations in Shanghai.
- EFPIA participated in the annual Russian Pharmaceutical Forum, bringing together senior industry executives and government stakeholders to discuss key challenges and healthcare solutions in Russia.
- EFPIA held a regulatory workshop with CPIA in Shanghai, focussing on common regulatory matters for the international and Chinese manufacturers.

SCIENCE POLICY AND REGULATORY AFFAIRS

- EFGCP and EFPIA organised a Lay summary conference with the ambition to get ready to increase the understandable information to patients who participate in trials and to pave the way for the implementation of the provisions of the Clinical Trials Regulation 536/2014.
- EFPIA and China Pharmaceutical Industry Association (CPIA) organized the annual China/EU Pharmaceutical Industry Forum in Shanghai.

SCIENCE POLICY AND REGULATORY AFFAIRS

EFPIA response to the consultation on the EU Commission Roadmap on Digital Transformation of Health and Care in the context of the Digital Single Market Strategy

STRATEGY AND HEALTHCARE SYSTEMS

- EFPIA DG Nathalie Moll participated in a joint EFPIA-Celgene session on pricing of pharmaceuticals and access to medicines during the European Health Forum Gastein.
- EFPIA organised a session on sharing of health data and the role of public-private partnerships during the eHealth conference of the Estonian EU Presidency in Tallinn.

INTERNATIONAL AFFAIRS

EFPIA co-organised the Joint Industry Turkey Strategy Session in Ankara, focussing on industry alignment and advocacy actions on key priorities of the industry, with sister associations AIFD and PhRMA.

SCIENCE POLICY AND REGULATORY AFFAIRS

- IMI Stakeholders forum on open innovation, patient engagement, microbiome
- Joint industry position paper on the value of institutional PPPs
- First EMA meeting with industry associations to discuss Brexit planning
- In collaboration with PhRMA, EFPIA published a report in on the benchmarking survey that looked into assessing the level of members implementation of the EFPIA-PhRMA Principles for Responsible Clinical Data Sharing.

COMMUNICATIONS AND PARTNERSHIPS

Patients and industry representatives from across the CEE region came together at a meeting in Bucharest to discuss how to support better collaboration for the benefit of patients across the region.

INTERNATIONAL AFFAIRS

EFPIA welcomed the entry into force of the EU-Japan FTA, where key priority of the industry, the expansion of the Mutual Recognition Agreement on GMP inspections was included.

SCIENCE POLICY AND REGULATORY AFFAIRS

- The joint industry associations overview of manufacturing and supply, regulatory, clinical trials and pharmacovigilance challenges due to Brexit and proposed solutions paper was prepared and finally endorsed by EFPIA.
- EFPIA submitted jointly with EuropaBio a response on European Commission Roadmap on the evaluation of the legislation of the medicines for children and rare diseases


COMMUNICATIONS AND PARTNERSHIPS

- Joint Patient - Cross Healthcare Industry Platform - An unprecedented opportunity to discuss key topics like outcomes focused healthcare, health collaboration post 2020 and best practices for working together

- #WeWontRest was translated in over 20 languages, in over 30 countries and seen by over 40 million people.

Continuing to drive innovation

With over 7000 medicines in development, the exciting new wave of medical innovation will play a key role in addressing the challenges faced by patients and healthcare systems




Within the next 5 years cutting edge developments in medicine will transform the lives of patients. These are the therapy areas set to make the biggest difference.



The impact of medicines

Medicines are some of the most powerful tools in treating and curing diseases



Hepatitis C (HCV)

15 million

people are living with Hepatitis C in Europe¹

+133%

cure rate increase for patients between 1999 and 2015⁵

95-96%

Hepatitis C is now curable in 95-96% of treated patients with only 8-12 weeks of treatment

Medicines have transformed HIV/AIDS from a death sentence to **a manageable diseases**

HIV/AIDS - Age Standardised Death Rate (ASDR)

-94%
FRANCE

-92%
SPAIN

CANCER

2 out of 3

Today, for European patients diagnosed in 2012, 2 out of 3 people diagnosed with cancer survive at least 5 years, compared with if they had been diagnosed a decade earlier⁶



Cardiovascular Disease



172

In Europe, biopharmaceutical companies are currently developing 172 medicines⁷ to treat heart disease, stroke and other cardiovascular diseases.

37%

New PCSK9 inhibitors have revolutionised therapy for high cholesterol. Between 2000 and 2012, the death rate from cardiovascular disease fell 37% in the EU5.⁸



⁶Calculations based on incidence figures quoted in Bengt Jönsson et al., Comparator Report on Patient Access to Cancer Medicines in Europe Revised, 2016 - page 16: 2000-2002 5-year survival rate in all cancers in Europe: 51.55% 2000-2007 5-year survival rate in all cancers across Europe: 54%; Incidence in 2012 in Europe: 2,707,000

⁷Medicines in Phase I through III of development. Source: 1) Health Advances analysis; PharmaProjects (accessed February 2016)

⁸2) WHO Mortality Database (accessed February 2016)

Collaboration

Europe is facing unprecedented healthcare challenges driven by an ageing population and increasing prevalence of chronic disease. Addressing these challenges requires greater levels of collaboration and new partnerships to tackle issues. As a partner in Europe's healthier future, EFPIA and its members are committed to addressing issues working with partners from across European research and health care communities. Below are just some examples of that work in practice.



Taking a transformative step in the fight against counterfeit medicines

The risk of falsified medicines entering the supply chain is a major and continuous threat for patient safety, public health and security in Europe. The creation of the European Medicines Verification System (EMVS) by manufacturers (Medicines for Europe, EFPIA, EAEPC), wholesalers (GIRP) and community pharmacists (PGEU) in response to the Falsified Medicines Directive represents a transformational step in the fight against falsified medicines, protecting patients across Europe. The EMVS means that, using a unique serial number, we can track medicines packs as they leave the manufacturer until they are authenticated and dispensed to the patient.



Supporting the measurement of patient outcomes

EFPIA and ICHOM (the International Consortium for Health Outcomes Measurement) signed a Strategic Alliance Partnership to work together to catalyze the measurement of standardized health outcomes as a step towards improving patient care through more sustainable, Value-Based Health Systems

European healthcare systems today face both unprecedented opportunities and challenges. Opportunities come in the form of medical science breaking new ground, delivering new advanced treatments for unmet health needs, and health informatics bringing new possibilities to harness health data for research, healthcare delivery optimization and better patient care. Challenges come in the form of ageing populations and increased incidence of chronic disease and multi-morbidities, which put healthcare systems under financial strain. Advancing the measurement of standardized health outcomes represents a critical shift towards a more efficient and effective healthcare system for patients, payers, hospitals, and providers.




Getting the patient perspective


The EFPIA Patient Think Tank provides a forum for an open exchange of ideas, information and perspectives between Patient Organisations and industry on topical issues impacting on patients. The aim of the Think Tank is to ensure that the patient voice is heard in the development of EFPIA policy and practice and to build trust and acceptance around transparent patient-industry dialogue and multi-stakeholder collaboration

No subject is off the table and as a group we have discussed topics such as outcomes focused healthcare, medicines pricing, patient engagement in HTA, healthcare data and collaboration. The Think Tank is keen to take dialogue and debate beyond the membership of the group, through initiatives like the Health Collaboration Summit and the “Working Together with Patient Groups” rollout programme.


EFPIA is a partner in the Innovative Medicines initiative (IMI), a Joint Technology Initiative (JTI) bringing together companies, universities, public laboratories, innovative SMEs, patient groups and regulators. IMI paves the way for breakthrough vaccines, medicines and treatments to tackle Europe's growing health challenges through a concentrated and combined science and innovation effort. Now in its tenth year IMI is putting Europe at the forefront of global medical innovation.



IMI Timeline 2017



IMI Key facts and figures 2017




€354 million 3 calls were launched, including 23 topics, with a total budget of € 354 million for which 25 proposals were selected for funding.

The economic impact of the industry


The research based pharmaceutical industry is one of Europe's **major high-technology industrial employers**.

Europe is a global leader in highly-skilled, science-based workforce



EU-28 Trade balance - High Technology Sectors

The biopharmaceutical industry makes a **significant contribution to the European economy**.



The impact of vaccines

General¹

Immunization currently **prevents** between



2,000,000 - 3,000,000

deaths every year. It is one of the most successful and cost-effective public health interventions.

An additional
1,500,000
deaths could be avoided, however, if global vaccination coverage improves.



More children are being immunized worldwide than ever before. During 2016, an estimated 116.5 million (about 86%) children under the age of one year worldwide received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine. These children are protected against infectious diseases that can cause serious illness or disability, and be fatal.




¹WHO 10 Facts on immunisation

INFLUENZA²



HPV³



²Annual public health and economic benefits of seasonal influenza vaccination: a European estimate (2014)

³Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe (2017) Authors: Hartwig et al.

⁴The economic burden of human papillomavirus-related precancers and cancers in Sweden (2017) Authors: Ostensson et al

⁵Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy (2017) Authors: Mennini et al.

EFPIA Members

FULL MEMBERS

ABBVIE	GLAXOSMITHKLINE	PFIZER
ALMIRALL	GRÜNENTHAL	PIERRE FABRE
AMGEN	IPSEN	ROCHE
ASTELLAS	JOHNSON & JOHNSON	SANOFI
ASTRAZENECA	LILLY	SERVIER
BAYER	LEO PHARMA	SHIRE
BOGEN	MENARINI	TAKEDA
BOEHRINGER INGELHEIM	MERCK	TEVA
BRISTOL MYERS SQUIBB	MSD	UCB
CELGENE	NOVARTIS	
CHIESI FARMACEUTICI	NOVO NORDISK	

AFFILIATE MEMBERS

BIAL
DAIICHI-SANKYO
EISAI
ESTEVE
H. LUNDBECK
ORION PHARMA
OTSUKA
THE MEDICINES COMPANY
VIFOR PHARMA

PARTNERS IN RESEARCH (PIR)

ALCEDIAG	MCKINSEY & COMPANY
BRUKER	MEDIDATA
CLARIVATE ANALYTICS	MEDTRONIC
COVANCE	NOKIA
DEXCOM	PIRAMAL
ELLEGARD MINIPIGS	PSYCHOGENICS
ERT	Q-LINEA
FUJIFILM	SAS
GE HEALTH	SCIENCE 37
ICON PLC	SOMALOGIC
ILLUMINA	VARIAN
INSTITUT MERIEUX	ZEISS
IQVIA	ZOETIS

EFPIA Member Associations

FULL MEMBERS

AUSTRIA Fachverband der Chemischen Industrie Österreichs (FCIO)	IRELAND Irish Pharmaceutical Healthcare Association (IPHA)	SPAIN Asociación Nacional Empresarial de la Industria Farmacéutica (Farmaindustria)
BELGIUM Association Générale de l'Industrie du Médicament (pharma.be)	ITALY Associazione delle imprese del farmaco (Farmindustria)	SWEDEN Läkemedelsindustriföreningen / The Swedish Association of the Pharmaceutical Industry (LIF/Sweden)
DENMARK Laegemiddelindustriforeningen The Danish Association of the Pharmaceutical Industry (LIF)	NETHERLANDS Vereniging Innovatieve Geneesmiddelen / Association Innovative Medicines	SWITZERLAND Verband der forschenden pharmazeutischen Firmen der Schweiz (Interpharma)
FINLAND Lääketeollisuus ry / Pharma Industry Finland (PIF)	NORWAY Legemiddelindustriforeningen / Norwegian Association of Pharmaceutical Manufacturers (LMI)	TURKEY Turkey Arastirmaci Ilac Firmalari Dernegi (AIFD)
FRANCE Les Entreprises du Médicament (LEEM)	POLAND Employers Union of Innovative Pharmaceutical Companies (Infarma)	UNITED KINGDOM The Association of the British Pharmaceutical Industry (ABPI)
GERMANY Verband Forschender Arzneimittelhersteller (VfA)	PORTUGAL Associação Portuguesa da Indústria Farmacêutica (Apifarma)	
GREECE Hellenic Association of Pharmaceutical Companies (SfEE)	RUSSIA Association of International Pharmaceutical Manufacturers (AIPM)	

AFFILIATE MEMBERS

BOSNIA & HERZEGOVINA Udruženje inovativnih proizvođača lijekova u BiH/Association of Research-Based Medicine Producers in Bosnia &Herzegovina	ESTONIA Association of Pharmaceutical Manufacturers in Estonia (APME)	MALTA Malta Maltese Pharmaceutical Association (PRIMA)
BULGARIA Association of the Research-based Pharmaceutical Manufacturers in Bulgaria (ARPharM)	HUNGARY Association of Innovative Pharmaceutical Manufacturers (AIPM)	ROMANIA Association of International Medicines Manufacturers (ARPIM)
CROATIA Innovative Pharmaceutical Initiative (IFI)	ICELAND Frumtök/The Icelandic R&D Pharmaceutical Association	SERBIA Innovative Drug Manufacturers' Association (INOVIA)
CYPRUS Cyprus Association of Pharmaceutical Companies (KEFEA)	LATVIA Association of International Research- based Pharmaceutical Manufacturers (SIFFA)	SLOVAKIA Slovak Association of Innovative Pharmaceutical Industry (AIFP)
CZECH REPUBLIC Association of Innovative Pharmaceutical Industry (AIFP)	LITHUANIA The Innovative Pharmaceutical Industry Association (IFPA)	SLOVENIA Forum of International Research and Development Pharmaceutical Industries (EIG)
	MACEDONIA Farmabrend Nova	UKRAINE Association of Pharmaceutical Research and Development (APRaD)

EFPIA Board Members

PRESIDENT		VICE-PRESIDENTS	
Stefan OSCHMANN (MERCK)		Olivier BRANDICOURT (SANOFI)	Jean-Christophe TELLIER (UCB)
Gitte AABO (LEO Pharma)	Murdo GORDON (BMS)	Giles PLATFORD (Takeda)	
Carlos ALBAN (AbbVie)	Peter GUENTER (Almirall)	António PORTELA (Bial)	
Mark ALLES (Celgene)	Allan HILLGROVE (Boehringer Ingelheim)	Iskra REIC (AstraZeneca)	
Gabriel BAERTSCHI (Grünenthal)	Anthony HOOPER (Amgen)	Adam SCHECHTER (MSD)	
Alberto CHIESI (Chiesi)	Paul HUDSON (Novartis)	Staffan SCHÜBERG (Esteve)	
Eric CORNUT (Menarini)	Olivier LAUREAU (Servier)	Kim STRATTON (Shire)	
Richard DANIELL (TEVA)	Yukio MATSUI (Astellas)	Dieter WEINAND (Bayer)	
Mike DOUSTDAR MAZIAR (Novo Nordisk)	David MEEK (Ipsen)	John YOUNG (Pfizer)	
Frédéric DUCHESNE (Pierre Fabre)	Luke MIELS (GSK)	Alfonso G. ZULUETA (Eli Lilly and Company)	
Johanna FRIEDLNADERER (Biogen)	Daniel O'DAY (Roche)		

EFPIA Specialised Groups

Vaccines Europe (VE) is the specialised vaccine industry group within EFPIA. It represents major innovative research-based global vaccine companies as well as small and medium sized enterprises operating in Europe.

VACCINES EUROPE MEMBERS		
ABBOTT BIOLOGICALS	MSD	TAKEDA
ASTRAZENECA	NOVAVAX	VAXEAL
CUREVAC	PFIZER VACCINES	
JANSSEN	SANOFI PASTEUR	
GLAXOSMITHKLINE VACCINES	SEQIRUS	

European Biopharmaceutical Enterprises (EBE) represents the voice of biopharmaceutical companies of all sizes in Europe and is a specialised group within EFPIA. Established in 2000, EBE is recognised as the leading biopharmaceutical association in Europe.

EBE MEMBERS		
ABBVIE	EVOTEC	NOVARTIS AG
AC IMMUNE	HEPTARES	NOVIMMUNE
ACHAOGEN	HOFFMANN-LA ROCHE	ORPHAN EUROPE*
AICURIS GMBH & CO. KG	GENESIS PHARMA	PHARMA MAR
ALK	GENFIT SA	POLYPHOR
AMGEN	GENOMIC HEALTH	PREGLEM SA
ASTRAZENECA	GLAXO SMITH KLINE	ROXALL*
BASILEA PHARMACEUTICA	HRA PHARMA	SANOFI
BAYER	IDOGEN	SPEROTHERAPEUTICS
BIO DEUTSCHLAND	IDORSIA	STALLERGENES-GREER
BIOGEN	INTREXON	SYMPHOGEN A/S
BIOPHYTIS	IPSEN	SYNTHON
BOEHRINGER INGELHEIM	IXALTIS	TIGENIX
CHIESI FARMACEUTICI*	JOHNSON & JOHNSON	TRANSGENE
CUREVAC	LABORATORIOS LETI	UCB PHARMA
DA VOLTERRA	LFB BIOTECHNOLOGIES	UNIQUEURE
DOMPE*	LYSOGENE	VAXEAL
ELI LILLY	MEDIMMUNE (ASTRAZENECA)	VISCOFAN
ENTASITHERAPEUTICS	MERCK KGA	ZYMENEX
ENYO PHARMA	MSD	
ERYPHARM	NETSCIENTIFIC	

* UNTIL JANUARY 2019



EFPIA Staff

GENERAL MANAGEMENT TEAM

Director General Nathalie Moll Chief of Staff Christine Berwaerts	PA to the Director General Maria Curatolo
--	---

COMMUNICATION AND PARTNERSHIPS

Executive Director Andy Powrie-Smith Communications Manager Zsófia Bakonyi Digital Communications Manager Giulia Biasi	Assistant Communications Manager Diem Tran Administrative Assistant Nathalie Bernardo
--	--

INTERNATIONAL AFFAIRS

Executive Director Koen Berden Deputy Director International Affairs Jana Nackberg	Manager International Affairs Réka Szántó Administrative Assistant Fabienne Muylle
---	---

PUBLIC AFFAIRS

Executive Director Elizabeth Kuiper Manager Public Affairs Ioana Enache	Assistant Manager Public Affairs Lenka Christiaens
--	--

STRATEGY AND HEALTHCARE SYSTEMS

Executive Director Thomas Allvin Senior Manager Healthcare Systems Roberta Savli	Administrative Assistant Nathalie Bernardo
---	--

LEGAL AFFAIRS

General Counsel Kristine Peers Director IP & Data Protection Brendan Barnes Director Legal Affairs & Compliance Julie Bonhomme	Ethics & Compliance Manager Versina Bregu IP Policy Manager Ania Jedrusik Administrative Manager Amelia Kossi
--	---

ECONOMIC & SOCIAL AFFAIRS

Executive Director François Bouvy Director Market Access/HTA Edith Frénoy Senior Manager, Country Support François Lamérant	Project Manager Market Access Mihai Rotaru Assistant Manager Luca Deplano
---	--

OFFICE MANAGEMENT

Chief of Staff Christine Berwaerts IT Manager Stéphane De Molling	Assistant Accounting & Administration Adèle N’Kashama Receptionist Pina Avola
--	--

SCIENCE POLICY AND REGULATORY AFFAIRS

Executive Director Magda Chlebus Director Regulatory Drug Development and Manufacturing Pär Tellner Director Regulatory Drug Development and Manufacturing Sini Eskola Senior Manager Research Partnerships Nicolas Creff Senior Manager Regulatory Drug Development & Manufacturing Silvia Garcia	Senior Manager Regulatory Drug Development & Manufacturing Giovanna Rizzetto Senior Manager Science Policy & Animal Welfare Kirsty Reid Senior Manager Science Policy Anna Szczepanska Assistant Manager Tatiana Kirpitchenok Assistant Manager Sandra Rodrigues
---	--

EUROPEAN BIOPHARMACEUTICAL ENTERPRISES (EBE)

Executive Director Barbara Freischem Public Affairs Manager Audrey Wolf	Office Manager Livia Le Metayer Regulatory Affairs Manager Véronique Debaut
--	--

VACCINES EUROPE (VE)


Executive Director Magdalena De Azero Senior Manager Anna Czwarno	Manager Policy and Government Affairs Andrija Visic Administrative Assistant Anne Meynaerts
--	--



European Federation of Pharmaceutical
Industries and Associations

EFPIA represents the pharmaceutical industry in Europe.

Through its direct membership of 36 national associations and 40 leading pharmaceutical companies, EFPIA provides the voice of 1,900 companies committed to researching, developing and bringing new medicines to improve health and quality of life around the world.



EFPIA Brussels Office
Leopold Plaza Building,
Rue du Trône 108,
B-1050 Brussels, Belgium
Tel: + 32 (0)2 626 25 66
www.efpia.eu * info@efpia.eu